New study aims to improve heart procedure outcomes for minority patients

NCT ID NCT06625801

Not yet recruiting Knowledge-focused Sponsor: ECRI bv Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This registry will enroll 1010 minority patients with complex coronary artery disease to see if using intravascular ultrasound (IVUS) during stent placement improves outcomes. The study tracks heart-related death, heart attacks, and need for repeat procedures over time. It aims to gather real-world data on how IVUS guidance works in underrepresented populations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could show that using IVUS during heart procedures improves outcomes for minority patients and helps reduce healthcare disparities.

What could go wrong

This is an observational registry, not a randomized trial, so it cannot prove cause and effect. Results may not apply to all populations or settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••